Evidence map›Paper›PMID 41340792›Full record

ArticleActa clinica Croatica2025

OPTIMIZATION OF HCV CELL CULTURE SYSTEM FOR EVALUATION OF ANTIVIRAL DRUGS AGAINST HCV GENOTYPES 2a AND 4a.

Naiera M Helmy, Reem El-Shenawy, Tawfeek H Abdelhafez, Ashraf A Tabll, Ana Petrović, Elizabeta Horvatić, Martina Smolić, Dominik Gjoni, Robert Smolić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naiera M HelmyMicrobial Biotechnology Department, Biotechnology Research Institute, National Research Center, Giza, Egypt.
Reem El-ShenawyMicrobial Biotechnology Department, Biotechnology Research Institute, National Research Center, Giza, Egypt.
Tawfeek H AbdelhafezMicrobial Biotechnology Department, Biotechnology Research Institute, National Research Center, Giza, Egypt.
Ashraf A TabllMicrobial Biotechnology Department, Biotechnology Research Institute, National Research Center, Giza, Egypt.
Ana PetrovićJosip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health in Osijek, Osijek, Croatia.
Elizabeta HorvatićJosip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health in Osijek, Osijek, Croatia.
Martina SmolićJosip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health in Osijek, Osijek, Croatia.
Dominik GjoniJosip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health in Osijek, Osijek, Croatia.
Robert SmolićJosip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health in Osijek, Osijek, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evaluation of hepatitis C virus (HCV) infection in cell culture is important for development of new antiviral agents and for understanding the viral life cycle, as well as the correlation among the genotypes spreading worldwide. Development of HCV cell culture systems offers great advantage by enabling growth of the virus in cell culture, allowing for discovery of potential therapeutics and vaccines. The aim of this study was to introduce the steps of HCV infection in the cell culture system as a determinant for the competence of more potent antiviral compounds. Two plasmids, JFH1 (genotype 2a) full length and 4a (ED43/C-NS2/NS5A) were subjected to

Indexed as

Antiviral AgentsCell Culture TechniquesHepacivirusGenotypeHumansRNA, ViralVirus ReplicationAntiviral AgentsRNA, ViralGenotype 4Hepatitis C virusHuh7.5InfectionJFH1

Identifiers

PMID41340792
PMCPMC12671704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.